Pancreatic Cancer Research

ResearcherYamaguchi UniversityActive in the last 2 years

Hidenori Takahashi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-4801-3540; OpenAlex author ID A5071232644, A5122780213. Sources: OpenAlex.

Their work

Papers
74 (first author 15, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
176
Papers, trials and grants by year

2011: 3 papers · 2012: 3 papers · 2013: 2 papers · 2014: 1 paper · 2015: 4 papers · 2016: 2 papers · 2017: 1 paper · 2018: 3 papers · 2019: 3 papers · 2020: 3 papers · 2021: 5 papers · 2022: 6 papers · 2023: 8 papers · 2024: 18 papers · 2025: 5 papers · 2026: 7 papers

Papers 50 of 74

  1. Preoperative Gemcitabine/Nab-Paclitaxel With Concurrent Radiation Therapy for Borderline Resectable Pancreatic Cancer: A Comparative Analysis With Preoperative… First author DOI 10.1002/ags3.70191↗
  2. Relationship Between Radiographic and Pathological Portal Vein-Superior Mesenteric Vein Involvement in Neoadjuvant Treatment for Pancreatic Cancer: A Comparati… First author DOI 10.1002/wjs.70395↗
  3. A prospective open label, multicenter phase 2 trial of full-dose gemcitabine and S-1 concurrent with radiation for locally advanced pancreatic ductal adenocarc… Co-author DOI 10.1007/s00595-026-03481-z↗
  4. Association between response to gemcitabine-based neoadjuvant therapy and efficacy of gemcitabine plus nab-paclitaxel for recurrent pancreatic ductal adenocarc… Co-author DOI 10.1007/s10147-026-03071-6↗
  5. Clinical significance of non-invasive in vitro drug sensitivity profiling using pancreatic cancer organoids derived from saline flushes collected during routin… Co-author DOI 10.1007/s12094-025-04111-9↗
  6. Reconsidering upfront surgery for resectable pancreatic ductal adenocarcinoma: The role of risk stratification and neoadjuvant chemotherapy. First author DOI 10.1016/j.suronc.2025.102333↗
  7. Randomized phase III trial of gemcitabine plus nab-paclitaxel versus gemcitabine plus S-1 as neoadjuvant chemotherapy for resectable pancreatic cancer in geria… Co-author DOI 10.1093/jjco/hyag055↗
  8. Discrepancy Between Radiographic and Pathological Response Assessment in Neoadjuvant Treatment for Pancreatic Cancer: A Comparison Between Neoadjuvant Chemothe… First author DOI 10.1002/ags3.70047↗
  9. The C11orf24 Gene as a Useful Biomarker for Predicting Severe Neutropenia in Modified FOLFIRINOX for Pancreatic Cancer. Co-author DOI 10.1111/cas.70087↗
  10. The effect of neoadjuvant chemoradiation therapy in resectable pancreatic cancer was independent of intratumoral vascularization. Co-author DOI 10.1186/s12876-025-04108-2↗
  11. Efficacy of SOAT1 Inhibitors Against Pancreatic Cancer with TP53 Mutations. Co-author DOI 10.1245/s10434-025-17482-8↗
  12. ASO Author Reflections: Efficacy of SOAT1 Inhibitors against Pancreatic Cancer with TP53 Mutations. Co-author DOI 10.1245/s10434-025-17667-1↗
  13. Removal of gemcitabine-induced senescent cancer cells by targeting glutaminase1 improves the therapeutic effect in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.34725↗
  14. Outcomes of patients with initially unresectable pancreatic cancer who underwent conversion surgery after FOLFIRINOX or gemcitabine plus nab-paclitaxel chemoth… Co-author DOI 10.1002/jhbp.12066↗
  15. Prognostic impact of aberrant right hepatic artery involvement in patients with pancreatic cancer: A multicenter retrospective cohort study. First author DOI 10.1002/jso.27792↗
  16. Diagnostic impact of postoperative CA19-9 dynamics on pancreatic cancer recurrence: a single-institution retrospective study. Co-author DOI 10.1007/s13304-024-01758-x↗
  17. Preoperative nutritional status is a useful predictor of the feasibility of postoperative treatment in octogenarian-plus pancreatic ductal adenocarcinoma patie… Co-author DOI 10.1016/j.ejso.2024.108650↗
  18. A striking elevation of CA19-9 after preoperative therapy negates prognostic benefit from radical surgery in resectable and borderline resectable pancreatic ca… Co-author DOI 10.1016/j.surg.2024.06.049↗
  19. Organ-specific variations in tumor marker dynamics in postoperative pancreatic cancer recurrence: Trends in lung and liver recurrence highlighting biological h… First author DOI 10.1016/j.suronc.2024.102103↗
  20. High N6-methyladenosine-activated TCEAL8 mRNA is a novel pancreatic cancer marker. Co-author DOI 10.1111/cas.16152↗
  21. The preliminary analysis of lymphatic flow around the connective tissues surrounding SMA and SpA elucidates patients' oncological condition in borderline-resec… Last author DOI 10.1186/s12893-024-02398-z↗
  22. ASO Author Reflections: A Novel Combination Index of Sialyl-Lewis Antigen-Related Tumor Markers Enhances Predictive Significance in Patients with a Modest Radi… First author DOI 10.1245/s10434-024-15021-5↗
  23. Skeletal Muscle-Derived Irisin Enhances Gemcitabine Sensitivity and Suppresses Migration Ability in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-024-15118-x↗
  24. Results of a Randomized Clinical Study of Gemcitabine Plus Nab-Paclitaxel Versus Gemcitabine Plus S-1 as Neoadjuvant Chemotherapy for Resectable and Borderline… Co-author DOI 10.1245/s10434-024-15199-8↗
  25. ASO Author Reflections: Which was the Better Regimen (Gemcitabine Plus Nab-Paclitaxel Versus Gemcitabine Plus S-1) as Neoadjuvant Chemotherapy for Localized Pa… Co-author DOI 10.1245/s10434-024-15244-6↗
  26. ASO Author Reflections: A Novel Mechanism of Anticancer Effect of Skeletal Muscle-Derived Irisin in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-024-15349-y↗
  27. Lymphocyte Antigen 6 Family Member D (LY6D) Affects Stem Cell Phenotype and Progression of Pancreatic Adenocarcinoma. Co-author DOI 10.21873/anticanres.17300↗
  28. Circulating tumor-associated antigen-specific IFNγ+4-1BB+ CD8+ T cells as peripheral biomarkers of treatment outcomes in patients with pancreatic cancer. Co-author DOI 10.3389/fimmu.2024.1363568↗
  29. Safety and Feasibility of Neoadjuvant-Modified FOLFIRINOX in Elderly Patients with Pancreatic Cancer. Co-author DOI 10.3390/cancers16142522↗
  30. [A Case of Pancreatic Cancer with Concomitant Pancreatic Metastasis of Renal Cell Carcinoma]. Co-author PMID 39948974↗
  31. Anti-tumor effect of avadomide in gemcitabine-resistant pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00280-023-04531-w↗
  32. Pancreatic cancer near the splenic hilum has a higher likelihood of splenic vessel invasion and unfavorable survival. First author DOI 10.1007/s00423-023-03089-8↗
  33. Rubicon can predict prognosis in patients with pancreatic ductal adenocarcinoma after neoadjuvant chemoradiotherapy. Co-author DOI 10.1007/s10147-023-02306-0↗
  34. Clinical Practice Guidelines for Pancreatic Cancer 2022 from the Japan Pancreas Society: a synopsis. Co-author DOI 10.1007/s10147-023-02317-x↗
  35. Pathological Nodal and Vascular Involvement Significantly Impacts the Recurrence Risk in Different Time Frames in Patients With Resectable and Borderline Resec… Co-author DOI 10.1097/sla.0000000000005879↗
  36. DUPAN-II normalisation as a biological indicator during preoperative chemoradiation therapy for resectable and borderline resectable pancreatic cancer. First author DOI 10.1186/s12885-023-10512-2↗
  37. Change Impact of Body Composition During Neoadjuvant Chemoradiotherapy in Patients with Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma U… Co-author DOI 10.1245/s10434-022-12985-0↗
  38. ASO Author Reflections: Neoadjuvant Chemoradiotherapy for Patients with Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma Undergoing Pancre… Co-author DOI 10.1245/s10434-022-13024-8↗
  39. New criteria of resectability for pancreatic cancer: A position paper by the Japanese Society of Hepato-Biliary-Pancreatic Surgery (JSHBPS). Co-author DOI 10.1002/jhbp.1049↗
  40. Establishment of a reference single-cell RNA sequencing dataset for human pancreatic adenocarcinoma. Co-author DOI 10.1016/j.isci.2022.104659↗
  41. Establishment of organoids using residual samples from saline flushes during endoscopic ultrasound-guided fine-needle aspiration in patients with pancreatic ca… Co-author DOI 10.1055/a-1713-3404↗
  42. Inhibition of Clusterin Represses Proliferation by Inducing Cellular Senescence in Pancreatic Cancer. Co-author DOI 10.1245/s10434-022-11668-0↗
  43. ASO Author Reflections: A Novel Mechanism of Suppressing Proliferation After Inhibition of Clusterin in Pancreatic Cancer. Co-author DOI 10.1245/s10434-022-11745-4↗
  44. New Screening System Using Forward-Viewing Radial Endoscopic Ultrasound and Magnetic Resonance Imaging for High-Risk Individuals With Familial History of Pancr… Last author DOI 10.3389/fmed.2022.928182↗
  45. Difference between carbohydrate antigen 19-9 and fluorine-18 fluorodeoxyglucose positron emission tomography in evaluating the treatment efficacy of neoadjuvan… First author DOI 10.1002/ags3.12418↗
  46. Tolerability of Nab-Paclitaxel Plus Gemcitabine as Adjuvant Setting in Japanese Patients With Resected Pancreatic Cancer: Phase I Study. Co-author DOI 10.1097/mpa.0000000000001702↗
  47. Randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine and nanoparticle albumin-bound paclitaxel combination therapy as neoadj… Co-author DOI 10.1186/s13063-021-05541-w↗
  48. Predictive Factors for Pancreatic Cancer and Its Early Detection Using Special Pancreatic Ultrasonography in High-Risk Individuals. Co-author DOI 10.3390/cancers13030502↗
  49. The Survival Benefit of Chemoradiotherapy following Induction Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Unresectable Locally Advanced Pancreatic Ca… Co-author DOI 10.3390/cancers13184733↗
  50. Clinical implications of the serum CA19-9 level in "biological borderline resectability" and "biological downstaging" in the setting of preoperative chemoradia… Co-author DOI 10.1016/j.pan.2020.05.020↗

Closest collaborators

The 25 strongest of 176 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yuichiro Doki · 32 shared papers, 2011–2026 · strength 5.42
  2. Hidetoshi Eguchi · 32 shared papers, 2011–2026 · strength 5.31
  3. Hirofumi Akita · 34 shared papers, 2011–2026 · strength 5.07
  4. Daisaku Yamada · 28 shared papers, 2019–2026 · strength 4.71
  5. Yoshifumi Iwagami · 21 shared papers, 2021–2026 · strength 3.82
  6. Yoshito Tomimaru · 21 shared papers, 2021–2026 · strength 3.79
  7. Tadafumi Asaoka · 19 shared papers, 2021–2026 · strength 3.42
  8. Kazuki Sasaki · 18 shared papers, 2022–2025 · strength 3.10
  9. Shinichiro Hasegawa · 12 shared papers, 2019–2026 · strength 2.08
  10. Masahiro Tanemura · 12 shared papers, 2011–2024 · strength 1.73
  11. Kunihito Gotoh · 13 shared papers, 2011–2026 · strength 1.56
  12. Tatsuya Ioka · 11 shared papers, 2013–2026 · strength 1.54
  13. Ryoji Takada · 10 shared papers, 2018–2026 · strength 1.52
  14. Kazuyoshi Ohkawa · 10 shared papers, 2018–2026 · strength 1.52
  15. Kenji Ikezawa · 8 shared papers, 2020–2026 · strength 1.34
  16. Osamu Ishikawa · 20 shared papers, 2011–2023 · strength 1.28
  17. Masato Sakon · 11 shared papers, 2015–2024 · strength 1.08
  18. Shigenori Nagata · 7 shared papers, 2012–2026 · strength 0.95
  19. Reiko Ashida · 7 shared papers, 2015–2025 · strength 0.89
  20. Yoshitaro Shindo · 4 shared papers, 2024–2026 · strength 0.89
  21. Hiroto Matsui · 4 shared papers, 2024–2026 · strength 0.89
  22. Yutaka Takeda · 6 shared papers, 2011–2026 · strength 0.84
  23. Hiroaki Nagano · 6 shared papers, 2011–2026 · strength 0.83
  24. Yugo Kai · 4 shared papers, 2021–2026 · strength 0.73
  25. Nobuyasu Fukutake · 6 shared papers, 2020–2022 · strength 0.72

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.